5-HT_1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective

Neurodegener Dis Manag. 2018 Aug;8(4):207-209. doi: 10.2217/nmt-2018-0017. Epub 2018 Jul 24.

Author

Philippe Huot^{1

2

3}

Affiliations

¹ Neurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, H3A 2B4, Canada.
² Department of Neurology & Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada.
³ Division of Neurology, McGill University Health Centre, Montreal, QC, H3A 2B4, Canada.

PMID: 30040029
DOI: 10.2217/nmt-2018-0017

No abstract available

Keywords: 5-HT1A; Parkinson's disease; dyskinesia; serotonin.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anti-Dyskinesia Agents / adverse effects
Anti-Dyskinesia Agents / pharmacology*
Anti-Dyskinesia Agents / therapeutic use*
Dyskinesia, Drug-Induced / drug therapy*
Dyskinesia, Drug-Induced / metabolism
Humans
Parkinsonian Disorders / drug therapy*
Parkinsonian Disorders / metabolism
Serotonin / metabolism
Serotonin 5-HT1 Receptor Agonists / pharmacology*
Serotonin 5-HT1 Receptor Agonists / therapeutic use

Substances

Anti-Dyskinesia Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin